NASDAQ · PHVS

Pharvaris N.V financials

$31.73−0.56%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Gross margin—————
Operating income-$199.2M-$151.6M-$107.1M-$93.0M-$61.6M
Net income-$206.6M-$139.5M-$111.6M-$81.9M-$48.6M
Net margin—————
Diluted EPS$-3.48$-2.58$-2.91$-2.43$-1.59
EBITDA-$198.8M-$151.3M-$106.8M-$92.9M-$61.5M
Operating cash flow-$160.8M-$125.0M-$102.9M-$72.0M-$50.7M
Free cash flow-$161.0M-$125.6M-$103.0M-$72.2M-$50.9M
Diluted shares59.2M54.0M38.4M33.6M30.4M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$342.2M$292.1M$432.5M$173.6M$238.1M
Short-term investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Total assets$353.7M$303.2M$440.7M$179.9M$241.2M
Total liabilities$35.4M$24.6M$16.2M$19.8M$8.1M
Shareholders' equity$318.3M$278.6M$424.5M$160.1M$233.1M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology